Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
Puma Biotechnology, Inc.
Cristina Saura; Mafalda Oliveira; Yin-Hsun Feng; Ming-Shen Dai; Shang-Wen Chen; Sara A Hurvitz; Sung-Bae Kim; Beverly Moy; Suzette Delaloge; William Gradishar; Norikazu Masuda; Marketa Palacova; Maureen E Trudeau; Johanna Mattson; Yoon Sim Yap; Ming-Feng Hou; Michelino De Laurentiis; Yu-Min Yeh; Hong-Tai Chang; Thomas Yau; Hans Wildiers; Barbara Haley; Daniele Fagnani; Yen-Shen Lu; John Crown; Johnson Lin; Masato Takahashi; Toshimi Takano; Miki Yamaguchi; Takaaki Fujii; Bin Yao; Judith Bebchuk; Kiana Keyvanjah; Richard Bryce; Adam Brufsky; NALA Investigators